CALGARY, May 2 /PRNewswire-FirstCall/ - Stem Cell Therapeutics Corp. (SCT) announced today that Dr. Joseph Tucker, President and CEO, will be presenting at the upcoming BioFinance conference at the Toronto Marriott Eaton Centre Hotel in Toronto, ON. Dr. Tucker is scheduled to present on Wednesday, May 03rd at 9am EST in the Trinity IV meeting room.
About BioFinance 2006: BioFinance 2006 is the Canadian Life Science industry’s leading investor conference. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient’s own stem cells to proliferate in the brain. SCT’s core technology, which includes its lead therapeutic product NTx(TM)-265, has been demonstrated to increase the number of innate adult stem cells that grow in place when this therapeutic approach is applied to test animals. SCT plans to develop this fundamental technology further for specific disease treatments such as stroke and potentially Huntington’s disease, Alzheimer’s disease and other neurodegenerative conditions.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward- looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
Stem Cell Therapeutics Corp.
CONTACT: Stem Cell Therapeutics Corp., visit www.stemcellthera.com orcontact : Dr. Joseph Tucker, Chief Executive Officer, Stem CellTherapeutics Corp., Phone : (403) 245-5495, info@stemcellthera.com
